Pralatrexate injection
Products billed under this code include Folotyn, Pralatrexate.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Folotyn, Pralatrexate.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Folotyn | Acrotech Biopharma LLC | 72893-0003-01 | 20 | $7,691.44 |
| Folotyn | Acrotech Biopharma LLC | 72893-0005-01 | 40 | $15,382.88 |
| Pralatrexate | Dr. Reddy's Laboratories Inc. | 43598-0342-11 | 20 | $7,691.44 |
| Pralatrexate | Dr. Reddy's Laboratories Inc. | 43598-0343-23 | 40 | $15,382.88 |
| Pralatrexate | FreseniUS Kabi USA, LLC | 65219-0550-01 | 20 | $7,691.44 |
| Pralatrexate | FreseniUS Kabi USA, LLC | 65219-0552-02 | 40 | $15,382.88 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $384.572 | −$1.55 | 1 MG | Pralatrexate injection | v1, posted September 17, 2026 |
| 3Q26 | $386.122 | −$6.597 | 1 MG | Pralatrexate injection | v1, posted September 15, 2026 |
| 2Q26 | $392.719 | $0.00 | 1 MG | Pralatrexate injection | v1, posted September 15, 2026 |
| 1Q26 | $392.719 | +$0.09 | 1 MG | Pralatrexate injection | v1, posted September 15, 2026 |
| 4Q25 | $392.629 | +$3.804 | 1 MG | Pralatrexate injection | v1, posted September 8, 2026 |
| 3Q25 | $388.825 | +$15.057 | 1 MG | Pralatrexate injection | v1, posted March 10, 2026 |
| 2Q25 | $373.768 | $0.00 | 1 MG | Pralatrexate injection | v1, posted March 10, 2026 |
| 1Q25 | $373.768 | $0.00 | 1 MG | Pralatrexate injection | v1, posted December 19, 2025 |
| 4Q24 | $373.768 | +$74.636 | 1 MG | Pralatrexate injection | v1, posted June 11, 2025 |
| 3Q24 | $299.132 | −$0.147 | 1 MG | Pralatrexate injection | v1, posted June 11, 2025 |
| 2Q24 | $299.279 | +$10.138 | 1 MG | Pralatrexate injection | v1, posted March 11, 2025 |
| 1Q24 | $289.141 | −$9.038 | 1 MG | Pralatrexate injection | v1, posted December 19, 2024 |
| 4Q23 | $298.179 | −$58.333 | 1 MG | Pralatrexate injection | v1, posted October 10, 2024 |
| 3Q23 | $356.512 | +$4.561 | 1 MG | Pralatrexate injection | v1, posted June 5, 2024 |
| 2Q23 | $351.951 | +$12.619 | 1 MG | Pralatrexate injection | v1, posted February 23, 2024 |
| 1Q23 | $339.332 | +$18.244 | 1 MG | Pralatrexate injection | v1, posted December 6, 2023 |
| 4Q22 | $321.088 | $0.00 | 1 MG | Pralatrexate injection | v1, posted June 22, 2023 |
| 3Q22 | $321.088 | $0.00 | 1 MG | Pralatrexate injection | v1, posted June 9, 2023 |
| 2Q22 | $321.088 | +$1.354 | 1 MG | Pralatrexate injection | v1, posted December 14, 2022 |
| 1Q22 | $319.734 | +$4.899 | 1 MG | Pralatrexate injection | v1, posted June 8, 2022 |
| 4Q21 | $314.835 | +$4.647 | 1 MG | Pralatrexate injection | v1, posted June 2, 2022 |
| 3Q21 | $310.188 | −$0.721 | 1 MG | Pralatrexate injection | v1, posted June 2, 2022 |
| 2Q21 | $310.909 | −$0.023 | 1 MG | Pralatrexate injection | v1, posted March 1, 2022 |
| 1Q21 | $310.932 | – | 1 MG | Pralatrexate injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.